| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2010 | EP2152701A1 Phenyl amino pyrimidine compounds and uses thereof |
| 02/17/2010 | EP2152700A1 Csf-1r inhibitors, compositions, and methods of use |
| 02/17/2010 | EP2152696A1 Aminopyrimidines useful as kinase inhibitors |
| 02/17/2010 | EP2152695A2 Gamma secretase modulators |
| 02/17/2010 | EP2152694A2 Thiazoles and pyrazoles useful as kinase inhibitors |
| 02/17/2010 | EP2152693A1 2-morpholin-4-yl-pyrimidines as pi3k inhibitors |
| 02/17/2010 | EP2152691A1 An improved process for preparing an optically active proton pump inhibitor |
| 02/17/2010 | EP2152690A1 Pyridyl piperidine orexin receptor antagonists |
| 02/17/2010 | EP2152689A1 Analogues of cilostazol |
| 02/17/2010 | EP2152688A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 02/17/2010 | EP2152686A1 Hydroxy sulfonate of quinone compounds and their uses |
| 02/17/2010 | EP2152679A1 Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions |
| 02/17/2010 | EP2152677A1 Acetamide derivatives as potassium channel modulators |
| 02/17/2010 | EP2152676A1 "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives" |
| 02/17/2010 | EP2152674A1 Benzimidazolone chymase inhibitors |
| 02/17/2010 | EP2152672A1 Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| 02/17/2010 | EP2152671A1 Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |
| 02/17/2010 | EP2152664A1 Dipeptide analogs as coagulation factor inhibitors |
| 02/17/2010 | EP2152663A2 Tri-aryl compounds and compositions comprising the same |
| 02/17/2010 | EP2152370A1 Aryl ether pyridazinone derivatives |
| 02/17/2010 | EP2152369A2 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes |
| 02/17/2010 | EP2152368A1 Substituted phosphonates and their use in decreasing amyloid aggregates |
| 02/17/2010 | EP2152321A1 Water treatment containing dbnpa for use in sanitizing recreational water |
| 02/17/2010 | EP2152316A2 Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system |
| 02/17/2010 | EP2152315A2 Sustained delivery formulations of risperidone compounds |
| 02/17/2010 | EP2152313A1 Oral nicotine formulation buffered with amino acid |
| 02/17/2010 | EP2152312A1 Low-viscous anthracycline formulation |
| 02/17/2010 | EP2152304A1 Nanoemulsion therapeutic compositions and methods of using the same |
| 02/17/2010 | EP2152285A1 Composition for maintaining androgen and androgen-like uptake potential by cells |
| 02/17/2010 | EP2152276A1 Screening assay to identify correctors of protein trafficking defects |
| 02/17/2010 | EP2152275A1 Methods of identifying genes involved in memory formation using small interfering rna(sirna) |
| 02/17/2010 | EP2152274A1 Nasal administration of benzodiazepines |
| 02/17/2010 | EP2152273A2 Polymerase inhibitors and the use thereof for the treatment of tumors |
| 02/17/2010 | EP2152272A2 Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| 02/17/2010 | EP2152271A1 Piperidine/piperazine derivatives |
| 02/17/2010 | EP2152270A1 Piperidine/piperazine derivatives |
| 02/17/2010 | EP2152269A1 Piperidine/piperazine derivatives |
| 02/17/2010 | EP2152268A1 Method of treating diabetes |
| 02/17/2010 | EP2152267A2 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 02/17/2010 | EP2152265A1 New method for preparing isofagomine and its derivatives |
| 02/17/2010 | EP2152263A1 Compositions useful for treating gastroesophageal reflux disease |
| 02/17/2010 | EP2152262A2 New heterocyclic derivatives useful for the treatment of cns disorders |
| 02/17/2010 | EP2152261A1 Treatment of virally induced lesions |
| 02/17/2010 | EP2152258A1 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof |
| 02/17/2010 | EP2152257A1 Diabetic wound healing |
| 02/17/2010 | EP2152256A2 Telomerase activating compounds and methods of use thereof |
| 02/17/2010 | EP2152255A1 Ophthalmic formulations of amyloid- contrast agents and methods of use thereof |
| 02/17/2010 | EP2152254A2 Resveratrol containing composition for modulating bone formation |
| 02/17/2010 | EP2152252A2 Selective proteasome inhibitors for treating diabetes |
| 02/17/2010 | EP2152249A1 Oral dosage form providing fast absorption of drug |
| 02/17/2010 | EP2152239A1 Stable oxaliplatin composition for parenteral administration |
| 02/17/2010 | EP2152238A2 Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| 02/17/2010 | EP2152237A1 Novel pharmaceutical composition |
| 02/17/2010 | EP2152236A1 Pharmaceutical composition of an anthracycline |
| 02/17/2010 | EP2152234A1 Lyophilized pharmaceutical compositions and methods of making and using same |
| 02/17/2010 | EP2152232A1 Methods and compositions for administration of oxybutynin |
| 02/17/2010 | EP2152227A1 A liquid formulation for administering nicotine |
| 02/17/2010 | EP2152102A2 Compositions, articles and methods for preventing or reducing tobacco-associated damage |
| 02/17/2010 | EP2152101A1 Milk fat-milk protein composition (preferably esterified with palmitic acid) for improving calcium absorption |
| 02/17/2010 | EP2152095A1 Food thickening agent, method for producing food thickening agent |
| 02/17/2010 | EP2152085A1 Erythropoietin complementation or replacement |
| 02/17/2010 | EP2152084A1 Method of manufacturing a ruthenium complex |
| 02/17/2010 | EP2152082A1 Tetracyclic inhibitors of fatty acid amide hydrolase |
| 02/17/2010 | EP2152081A1 Novel compounds |
| 02/17/2010 | EP2152080A1 Novel soluble 1,4 benzodiazepine compounds and stable salts thereof |
| 02/17/2010 | EP2152079A1 Heterocyclic compounds and uses thereof |
| 02/17/2010 | EP2152078A1 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| 02/17/2010 | EP2152074A1 Compositions of (-)-e-10-oh-nt and methods for their synthesis and use |
| 02/17/2010 | EP2091942B1 Substituted pyrazinone derivatives for use as a medicine |
| 02/17/2010 | EP2049092B1 Compositions with enhanced elasticizing activity |
| 02/17/2010 | EP2038285B1 Adenosine a2a receptor antagonists |
| 02/17/2010 | EP1979321B9 Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |
| 02/17/2010 | EP1922074B1 A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma. |
| 02/17/2010 | EP1898721B1 Method for producing an aqueous suspension and a powdered preparation of one or more carotinoids |
| 02/17/2010 | EP1893213B1 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases |
| 02/17/2010 | EP1828200B1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease. |
| 02/17/2010 | EP1809125B1 Nutrition containing fat blend |
| 02/17/2010 | EP1773827B1 Benzothiazole derivatives |
| 02/17/2010 | EP1758888B1 Butyrylcholinesterase selective inhibitors |
| 02/17/2010 | EP1606021B1 Manganese based organometallic complexes, pharmaceutical compositions and dietetic products |
| 02/17/2010 | EP1581215B1 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 02/17/2010 | EP1578919B1 Endogenous retrovirus up-regulated in prostate cancer |
| 02/17/2010 | EP1551839B1 Process for preparing 9-¬4-acetoxy-3-(acetoxymethyl)but-1-yl -2-aminopurine |
| 02/17/2010 | EP1549322B1 Lipid a and other carbohydrate ligand analogs |
| 02/17/2010 | EP1549318B1 Crystal structure of aurora-2 protein and binding pockets thereof |
| 02/17/2010 | EP1536781B1 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | EP1490013B1 Methods for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising hydroxyurea |
| 02/17/2010 | EP1487810B1 4-(diarylmethyl)-1-piperazinyl derivatives |
| 02/17/2010 | EP1451163B1 3-amido-1,2-benzoisoxazole derivatives, process for preparation, and use thereof |
| 02/17/2010 | EP1420775B1 Platinum complexes and their uses in therapy |
| 02/17/2010 | CN201404486Y Controlled-release micro sphere of chitosan coating 3,5-dyhydroxy-4-isopropyl toluylene |
| 02/17/2010 | CN101652143A A composition for selective serotonin reuptake inhibition and process thereof |
| 02/17/2010 | CN101652142A mineralocorticoid receptor antagonists |
| 02/17/2010 | CN101652141A modified dosage forms of tacrolimus |
| 02/17/2010 | CN101652140A Enantiomeric compounds with antibacterial activity |
| 02/17/2010 | CN101652139A Pharmaceutical composition |
| 02/17/2010 | CN101652137A Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone |
| 02/17/2010 | CN101652136A Unit dose formulations and methods of treating thrombosis with an oral factor XA inhibitor |
| 02/17/2010 | CN101652135A Novel use of genistein |